Aligos Therapeutics (ALGS) Assets Average (2020 - 2026)
Aligos Therapeutics' (ALGS) quarterly Assets Average came in at $76.5 million in Q1 2026, down 30.66% YoY from $110.4 million in Q1 2025, and down 22.8% on a QoQ basis from $99.1 million in Q4 2025.
Aligos Therapeutics (ALGS) Assets Average (2020 - 2026) Analysis & Trends
Aligos Therapeutics (ALGS) has 7 years of Assets Average data on file, last reported at $76.5 million in Q1 2026.
- Quarterly Assets Average fell 30.66% year-over-year to $76.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $76.5 million (down 30.66% YoY) and the FY2025 annual result came in at $79.3 million, down 28.42% from the prior year.
- Assets Average fell to $76.5 million in Q1 2026, from $99.1 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $222.9 million in Q1 2022 to a low of $76.5 million in Q1 2026.
- A 5-year average of $129.3 million and a median of $118.7 million in 2023 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2023 — Assets Average plunged 44.61% — and 2025, when it rose 25.09%.
- Tracing ALGS's Assets Average over 5 years: stood at $155.4 million in 2022, then decreased by 23.61% to $118.7 million in 2023, then plunged by 33.22% to $79.3 million in 2024, then grew by 25.09% to $99.1 million in 2025, then fell by 22.8% to $76.5 million in 2026.
- The last three Assets Average figures came in at $76.5 million (Q1 2026), $99.1 million (Q4 2025), and $122.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | Aligos Therapeutics | 68.90 Mn | 38.45 Mn | - | 65.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 65.44 Mn |
| Mar 31, 2026 | 76.55 Mn |
| Dec 31, 2025 | 99.15 Mn |
| Sep 30, 2025 | 122.24 Mn |
| Jun 30, 2025 | 142.70 Mn |
| Mar 31, 2025 | 110.40 Mn |
| Dec 31, 2024 | 79.26 Mn |
| Sep 30, 2024 | 98.62 Mn |
| Jun 30, 2024 | 118.36 Mn |
| Mar 31, 2024 | 139.71 Mn |
| Dec 31, 2023 | 118.69 Mn |
| Sep 30, 2023 | 95.99 Mn |
| Jun 30, 2023 | 113.93 Mn |
| Mar 31, 2023 | 134.22 Mn |
| Dec 31, 2022 | 155.38 Mn |
| Sep 30, 2022 | 173.30 Mn |
| Jun 30, 2022 | 196.50 Mn |
| Mar 31, 2022 | 222.92 Mn |
| Dec 31, 2021 | 249.22 Mn |
| Sep 30, 2021 | 237.47 Mn |